Public Oath
|
Clean Up Crew
|
Investigations
|
Expert Opinions
|
Public Forum
|
Investment Tools
|
Background Checks
Street Patrol
Under Surveillance
Penny Pincher
Interrogation Room
Volunteer Deputies
Loaded Weapons
Rap Sheet
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Accentia Biopharmaceuticals, Inc.
(OP:
ABPI
)
0.0170
USD
UNCHANGED
Official Closing Price
/ Updated:
8:10 PM EDT, May 20, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
47,696
Open
0.0179
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0170
Today's Range
0.0170 - 0.0179
52wk Range
0.0110 - 0.2800
Shares Outstanding
89,755,901
Dividend Yield
N/A
Top News
More News
Biovest Files Recapitalization Plan to Strengthen Balance Sheet and Advance Commercialization Strategy for BiovaxID™ Cancer Vaccine
March 07, 2013
from
Business Wire News Releases
Biovest to Present BiovaxID™ Cancer Vaccine Update at Lymphoma Coalition Patient Advocacy Event prior to ASH Meeting
December 04, 2012
from
Business Wire News Releases
More News
Read More
Biovest Conducts Meeting with EMA Advancing Process to Seek EU Approval for Cancer Vaccine
September 20, 2012
from
Business Wire News Releases
Biovest Names Lymphoma Key Opinion Leader from MD Anderson Cancer Center to Scientific Advisory Board
September 11, 2012
from
Business Wire News Releases
Biovest Conducts End of Phase III Review with FDA of BiovaxID™ as Consolidation Therapy in Non-Hodgkin’s Lymphoma
August 14, 2012
from
Business Wire News Releases
Biovest Advances Process Seeking European Marketing Approval for BiovaxID™ Personalized Lymphoma Vaccine
July 30, 2012
from
Business Wire News Releases
Max Planck Institute Presents Study Positioning Biovest Bioreactor Systems as Potential Novel Viral Vaccine Manufacturing Platform
July 19, 2012
from
Business Wire News Releases
Biovest’s BiovaxID® Lymphoma Vaccine Featured in FierceBiotech Cancer Immunotherapy Special Report
July 18, 2012
from
Business Wire News Releases
Biovest’s Eligibility to Seek EU Marketing Approval for its BiovaxID Cancer Vaccine as Orphan Drug Confirmed by EMA
July 12, 2012
from
Business Wire News Releases
Biovest Initiates Formal Regulatory Approval Process for BiovaxID® Cancer Vaccine in Europe
June 20, 2012
from
Business Wire News Releases
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here